Eliminating Hepatitis C Transmission By Enhancing Hepatitis C Care And Treatment In Primary Health Care Settings.
Funder
National Health and Medical Research Council
Funding Amount
$1,221,831.00
Summary
In developed countries, people who inject drugs (PWID) are the group at greatest risk of hepatitis C (HCV) infection but few PWID receive HCV treatment. With the advent of highly effective non-interferon based treatments HCV elimination, although ambitious, is now being seriously considered globally. This partnership grant will explore the feasibility of eliminating HCV transmission by enhancing HCV care and treatment for PWID in primary health care settings.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Gene Expression Profiling In Critically Ill Patients With Septic Shock: The ADRENAL-GEPS Study
Funder
National Health and Medical Research Council
Funding Amount
$863,304.00
Summary
Sepsis refers to a whole body inflammation caused by severe infection. Approximately one in three adults admitted with septic shock die within 28 days and it is unclear whether treatment with anti-inflammatory drugs is beneficial in terms of patient survival. The aim of this study is to develop a clinical test based on gene activity that can be used to predict patient survival and also determine what the best treatment might be for individual patients.
The D-Health Trial: A Large-scale Population-based Trial Of Vitamin D Supplementation For Improving The Health Of Older Adults
Funder
National Health and Medical Research Council
Funding Amount
$2,591,860.00
Summary
The D-Health Trial is a randomised placebo-controlled trial of vitamin D supplementation for improving the health of older Australian adults. Over 21,000 people were recruited and randomised to monthly doses of vitamin D or placebo. This grant will enable completion of the planned 5 years of supplementation and long-term follow-up of mortality and cancer. The results of the trial will inform decisions about food fortification and/or supplementation with vitamin D.
Improving Skin Cancer Prevention: Motivating Preventive Behaviours Using Knowledge Of Personalised Genomic Risk Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$1,041,720.00
Summary
The aim of our study is to evaluate whether we can improve the Australian public’s skin cancer prevention behaviours, particularly reducing exposure to ultraviolet (UV) radiation, by giving personalised information about melanoma genetic risk. We will also explore the psycho-social, ethical, and economic implications of receiving this information. The results of our study are likely to influence the future of skin cancer prevention in Australia.
Individualising Care For Patients With Chronic Hepatitis C: Predicting Side Effects And Treatment Response Using Genomic And Proteomic Approaches.
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially impro ....Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.Read moreRead less
Treatment Of Invasively Ventilated Adults With Early Activity And Mobilisation
Funder
National Health and Medical Research Council
Funding Amount
$1,467,137.00
Summary
The sickest patients in intensive care units (ICUs) receive prolonged, invasive support for their breathing. This is currently managed with complete bed rest, and results in severe muscle weakness, increased duration of hospital stay and poor recovery. We have found that early activity and mobilisation during invasive breathing support is safe and may improve survival and recovery. We will test early activity and mobilisation in a large randomised controlled trial of 750 ICU patients.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,499,145.00
Summary
Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.